In UK practice, those are regulatory and patient-safety questions first, and treatment questions second
Gastrointestinal effectsparticularly nausea, vomiting, diarrhea, and constipationaffect 40-50% of patients, especially during dose escalation
However, there have been instances where individuals experienced cramping, bloating, and depleted zinc levels
pharmacy benefit managers include the companys full obesity portfolio on formularies
Combined GH release drives stronger IGF-1 upregulation in hepatocyte and myoblast assays
Medications containing GLP-1 have been used to treat type-2 diabetes for many years, but have only recently been considered an option to regulate weight management